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pH-dependent Internalization of Muramyl Peptides from Early
Endosomes Enables Nod1 and Nod2 Signaling
Abstract
Nod1 and Nod2 are members of the Nod-like receptor family that detect intracellular bacterial
peptidoglycan-derived muramyl peptides. The biological effects of muramyl peptides have been
described for over three decades, but the mechanism underlying their internalization to the cytosol
remains unclear. Using the human epithelial cell line HEK293T as a model system, we demonstrate here
that Nod1-activating ligands entered cells through endocytosis, most likely by the clathrin-coated pit
pathway, as internalization was dynamin-dependent but not inhibited by methyl-beta-cyclodextrin. In
the endocytic pathway, the cytosolic internalization of Nod1 ligands was pH-dependent, occurred prior
to the acidification mediated by the vacuolar ATPase, and was optimal at pH ranging from 5.5 to 6.
Similarly, the Nod2 ligand MDP was internalized into host cytosol through a similar pathway with
optimal pH for internalization ranging from 5.5 to 6.5. Moreover, Nod1-activating muramyl peptides
likely required processing by endosomal enzymes, prior to transport into the cytosol, suggesting the
existence of a sterically gated endosomal transporter for Nod1 ligands. In support for this, we identified
a role for SLC15A4, an oligopeptide transporter expressed in early endosomes, in Nod1-dependent
NF-kappaB signaling. Interestingly, SLC15A4 expression was also up-regulated in colonic biopsies
from patients with inflammatory bowel disease, a disorder associated with mutations in Nod1 and Nod2.
Together, our results shed light on the mechanisms by which muramyl peptides get access to the host
cytosol, where they are detected by Nod1 and Nod2, and might have implications for the understanding
of human diseases, such as inflammatory bowel disease.
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Nod1 and Nod2 are members of the Nod-like
receptor family that detect intracellular
bacterial peptidoglycan-derived muramyl
peptides. The biological effects of muramyl
peptides have been described for over three
decades but the mechanism underlying their
internalization to the cytosol remains unclear.
Using the human epithelial cell line HEK293T
as a model system, we demonstrate here that
Nod1-activating ligands entered cells through
endocytosis, most likely by the clathrin-coated
pit pathway, as internalization was dynamin-
dependent but not inhibited by methyl-β-
cyclodextrin. In the endocytic pathway, the
cytosolic internalization of Nod1 ligands was
pH-dependent, occurred prior to the
acidification mediated by the V-ATPase and
was optimal at pH ranging from 5.5 to 6.
Similarly, the Nod2 ligand MDP was
internalized into host cytosol through a
similar pathway with optimal pH for
internalization ranging from 5.5 to 6.5.
Moreover, Nod1-activating muramyl peptides
likely required processing by endosomal
enzymes, prior to transport into the cytosol,
suggesting the existence of a sterically-gated
endosomal transporter for Nod1 ligands. In
support for this, we identified a role for
SLC15A4, an oligopeptide transporter
expressed in early endosomes, in Nod1-
dependent NF-κB signaling. Interestingly,
SLC15A4 expression was also upregulated in
colonic biopsies from patients with
inflammatory bowel disease, a disorder
associated with mutations in Nod1 and Nod2.
Together, our results shed light onto the
mechanisms by which muramyl peptides get
access to the host cytosol, where they are
detected by Nod1 and Nod2, and might have
implications for the understanding of human
diseases, such as inflammatory bowel disease.
Innate immunity relies on the detection of
conserved microbial- or danger-associated
molecular patterns (MAMPs or DAMPs), by
pattern-recognition molecules (PRMs). In
mammals, several families of PRMs have been
recently identified, including the transmembrane
Toll-like receptors (TLRs), cytosolic Nod-like
receptors (NLRs) and RIG-I-like receptors
(RLRs) (1). NLR proteins include Nod1 and
Nod2, which trigger pro-inflammatory pathways
such as NF-κB and MAP kinases, in response to
bacterial peptidoglycan (2), and NLRPs (also
known as Nalps), such as NLRP1 and NLRP3,
which induce the activation of caspase-1
inflammasomes in response to various MAMPs
and DAMPs (3).
In the case of TLRs, there is
accumulating evidence that the sub-cellular
localization and the function of these PRMs is
tightly associated, at multiple levels, with
endocytosis and phagocytosis, which represent
evolutionary conserved mechanisms for the
internalization of small (<0.5µm) and large
(>0.5µm) particles, respectively. Indeed, while
some TLRs are expressed at the plasma
membrane, others (such as TLR3, 7 and 9) are
found predominantly associated with the
endoplasmic reticulum (ER) and endosomal
compartments, where they detect their respective
microbial-derived nucleic acid MAMPs (4). In
particular, TLR9 has been shown to move from
the ER to CpG DNA-containing endosomes,
2concurrent with the accumulation of MyD88,
thus showing that endosomes represent the
physiological location where TLR9-dependent
signaling arises (5). In addition, studies on TLR4
have demonstrated that lipopolysaccharide (LPS)
is  endocytosed by a receptor-mediated
mechanism dependent on dynamin and clathrin
and colocalized with TLR4 on early/sorting
endosomes (6). In the case of this TLR, it is
believed that endosomal trafficking is associated
with termination of the MyD88-dependent pro-
inflammatory signal (6). In contrast, TLR4 in
early endosomes has been shown recently to
engage TRAM and TRIF adaptors, resulting in
the ignition of type I interferon signaling in
response to lipopolysaccharide (LPS) (7).
Therefore, the nature of the cellular response to
LPS is dependent upon the sub-cellular
localization of TLR4, thus reinforcing the
importance of the interplay between TLR
signaling and endosomal trafficking.
A number of studies have also linked
TLR signaling with phagosome maturation.
While it remains controversial whether TLR-
dependent signaling actually drives phagosomal
maturation (8,9), it is clear that the processing of
engulfed microbes within phagosomes regulates
the availability of MAMPs within this
compartment. Accordingly, Herskovits et al.
have recently demonstrated that, in interferon
gamma-activated macrophages, the degradation
of Listeria monocytogenes in the phagolysosome
generates bacterial molecules, which could
specifically trigger type I interferon responses
through a Nod2-dependent pathway (10). This
interesting observation suggests that innate
immune signaling and microbial degradation
within the phagolysosome are processes that are
intimately linked. It also provides support to the
concept that Nod-dependent signaling is
associated with intracellular vesicular trafficking.
Nod1 and Nod2 both detect specific
structures from bacterial peptidoglycan (11).
While Nod2 detects muramyl dipeptide (MDP)
(12,13), a motif found in almost all bacteria,
Nod1 specifically senses diaminopimelic acid
(DAP)-containing muramyl peptides (14,15). In
particular, human Nod1 preferentially detects N-
acetylmuramyl-L-Ala-D-Glu-mesoDAP (M-Tri-
DAP) (16), and the minimal motif for Nod1-
dependent sensing is the dipeptide D-Glu-
mesoDAP (iE-DAP) (11,14). Interestingly, long
before the identification of Nod1 and Nod2 as
sensors of muramyl peptides and bacterial
peptidoglycan, the biological activities of these
bacterial-derived molecules had been studied
extensively (17,18). It is well documented that
these muramyl peptides trigger a multitude of
immune responses, such as the induction of
cytokines/chemokines, the production of nitric
oxide and reactive oxygen species and the
clearance of microbes by phagocytic cells
( 1 7 , 1 8 ) . A considerable literature also
demonstrated that these muramyl peptides
synergize with MAMPs detected by TLRs, such
as LPS (19). While the identification of Nod1
and Nod2 as sensors of muramyl peptides has
provided an acceleration in this field of
investigation, it also brought the question of how
such microbial molecules could get access to the
host cytosol, where Nod1 and Nod2 reside.
Interestingly, research aiming at improving the
biological activities of these muramyl peptides
demonstrated early on that the addition of
lipophilic groups to these molecules enhanced
their activity considerably, suggesting that their
internalization was likely a key factor in
determining their efficiency (20-23).
The mechanisms by which muramyl
peptides get access to the host cytosol remain
unclear. This question is of fundamental
importance for our understanding of Nod-
dependent signaling, and potentially holds broad
therapeutic implications. Indeed, mutations in
Nod1  and Nod2 have been associated with
inflammatory bowel disease (IBD) in humans
(24). In particular, Nod2 has been identified as
the first susceptibility gene for Crohn’s disease
(25,26).
In this manuscript, we used the
HEK293T epithelial cell line to study the
mechanism of internalization of Nod1 ligands.
We demonstrated that these peptidoglycan-
derived molecules enter cells by endocytosis, and
that the composition of the Nod1-activating
molecules dramatically affected their intrinsic
uptake capacity. Our data also suggested that this
internalization was mediated by clathrin-
dependent endocytosis, as internalization of
Nod1 ligands required dynamin and was
independent from caveolae. Further, we showed
that, within endosomes, the internalization of
Nod1 ligands was critically dependent on pH,
and was optimal at pH ranging from 5.5 to 6,
which are characteristic of early endosomes.
Accordingly, internalization of Nod1-activating
molecules did not require the action of the
vacuolar ATPase (V-ATPase) complex. We also
provide evidence that the Nod2 ligand MDP
3enters cells through a similar endocytic process.
Our results also show that the internalization of
Nod1 ligands is a process that is sterically gated,
and likely requires the action of hydrolytic
endosomal enzymes prior to transport into the
cytosol, thus suggesting the existence of one or
several specific transporters for Nod1 ligands in
early endosomes. Using knock-down assays, we
identified SLC15A4 as a putative transporter for
Nod1 ligands in early endosomes. SLC15A4
expression was found to be significantly
upregulated in tissue biopsies from IBD patients,
therefore highlighting a potential role for the
modulation of peptidoglycan access to the
cytosol in IBD etiology. Together, our results
uncover the mechanism by which Nod ligands
traffic into cells and get access to the cytosol
where they are detected by Nod1 and Nod2. Our
observations also highlight the previously
unappreciated link between endosomal
acidification/maturation and Nod-dependent
signaling.
EXPERIMENTAL PROCEDURES
Cell culture and Reagents—Human embryonic
kidney epithelial cell line HEK293T (American
Type Culture Collection) was cultured in
Dulbecco’s modified Eagle’s medium (DMEM),
supplemented with 5% Fetal Calf Serum (FCS)
and 1% penicillin/streptomycin. Cells were
maintained in 95% air, 5% CO2 at 37ºC.
Endotoxin-free FCS and phosphate buffer saline
(PBS) were from Wisent (St-Bruno, Quebec).
FCS was used after heat inactivation at 56ºC for
30 min. All cell culture reagents and antibiotics
were also from Wisent.
Nod1 ligands, iE-DAP (γ -D-Glu-
mesoDAP), Tri-DAP (L-Ala-D-Glu-mesoDAP),
M-Tri-DAP (MurNAc-L-Ala-D-Glu-mesoDAP),
C12-iE-DAP, were from InvivoGen. iE-DAP,
Tri-DAP and M-Tri-DAP were used at
concentrations ranging from 1 to 10 µg / m l
whereas C12-iE-DAP was used from 0.01 to 1
µg/ml. Nod2 ligand, muramyl dipeptide (MDP)
was also from InvivoGen and used at a
concentration of 10 µg/ml.
The inhibitors of endocytosis were
purchased from Sigma and used at the following
concentrations : valinomycin (1-10 µM ) ,
bafilomycin A1 (10-50 nM), dynasore
monohydrate (80 µM), nocodazole (1 µg/ml),
cytochalasin D (1 µg/ml), carbonyl cyanide m-
cholorophenylhydrazone (CCCP) (1-10 µM),
methyl-β-cyclodextrin (2.5 to 10 mM).
Extracellular acidification assays— To examine
the effect of extracellular pH on ligand uptake,
isotonic buffer (IB) (50 mM HEPES, pH 7, 100
mM KCl, 3 mM MgCl2, 0.1 mM DTT, 85 mM
sucrose, 0.2% BSA, 1 mM ATP and 0.1 mM
GTP) was prepared with pH modified to 5, 5.5,
6, 6.5, or 7, and ATP, DTT and GTP were added
freshly for each experiment. Cells were then
incubated for 1 hour at 37ºC with the respective
ligands in 500 µ l IB at varying pH.
Subsequently, IB was removed and replaced with
DMEM plus 5% fetal-calf serum for 5 hours
before performing luciferase measurements.
NF-κB activation assays— Transfections were
carried out using polyethylenimine (PEI,
Polysciences Inc., Warrington, PA) in HEK293T
according to the manufacturer’s instructions.
Briefly, cells were transfected overnight with 75
ng of NF-κB luciferase reporter plamid (Igκ-luc,
Invitrogen). The empty vector (pcDNA3.1,
Invitrogen) was used to balance the transfected
DNA concentration. The expression vector for
human Nod2 (0.2 ng/well) was a kind gift from
Dr. Nunez (University of Michigan, Ann Arbor,
MI). Following transfection, Nod1 or Nod2
ligands were added the next day for 6 hours
(unless specified) before performing luciferase
measurements. For NF-κB activation assays in
digitonin-permeabilized cells, HEK293T were
incubated for 10 min at 37°C with Nod1 ligands
in isotonic digitonin buffer (DB) (500 µl) with or
without 10 µg/ml digitonin (Sigma), and then
placed in DMEM for 6 hours, as previously
described (15).
As a control for the possible toxicity of
the trafficking inhibitors used towards NF-κB
activation, we systematically transfected over-
night the Igκ-luci reporter vector together with
50 ng of expression vector encoding for Rip2
(from Dr Thome, UNIL, Lausanne), the Nod1
adaptor protein acting downstream of the
detection of peptidoglycan by Nod1. In all the
experiments presented in this study, the doses of
the drugs used had no effect on Rip2-mediated
activation of NF-κB (data not shown).
NF-κB-dependent luciferase assays were
performed in duplicate, and data represent at
least three independent experiments. Data show
mean ± S.E.
4Immunofluorescence— HEK293T cells were
incubated in DMEM without FCS for 1 hour
prior to incubation in IB at pH 5.5 or 7 plus
transferrin conjugated to Alexa Fluor 568 (10
µg/ml, Molecular Probes Inc.) for 1 hour at
37°C. Rab5-RFP expression vector was a kind
gift from Dr. John Brumell (the Hospital for Sick
Children, Toronto). SLC15A4-V5 was obtained
from Dr Knipp (The State University of New
Jersey, NJ). Cells were cotransfected with either
Rab5-RFP (500 ng) or SLC15A4-V5 (500 ng) or
both overnight, and incubated in IB at pH 5.5 or
7 for 1 hour at 37°C the next day. Cells were
then washed with cold PBS, fixed for 15 minutes
at room temperature with paraformaldehyde
(3.7% w/v in PBS), permeabilized with 0.1%
TritonX-100 for 5 min, stained with anti-V5
(anti-mouse-FITC) for 1 hour and mounted with
Vectashield (Vector Laboratories, CA).
Coverslips were visualized on a Carl Zeiss
Axiovert 200 microscope with a 63X oil
fluorescence objective.
Semi-quantatative PCR- Total RNA samples
from untreated cells were prepared according to
t h e  manufacturer’s protocols (Qiagen,
Mississauga, ON). After genomic DNA
elimination with RNase-free DNase, the
complementary DNA was generated from 1 µg
RNA using a mixture of oligo-dT and random
primers and Omniscript Reverse Transcriptase
(Qiagen, ON). PCR was performed with Taq
Polymerase (Invitrogen) using the following
primers:
5’ -TTGCTTCTGGTCGTCTGTG3’ ,  5’ -
GCCCCTGACATGAAATATGG  3’ for
SLC15A1, 5’-GCCCTGTCTTGAAGCATTTT-
3’, 5’-AGAGTCTCTGGGGCCTTGTT-3’ for
SLC15A2, 5’-GCTTAAGCTCGCTCTCCAAA-
3’,5’-GCAAGATCTTCACCAGCAC-3’ for
SLC15A3, 5’-AGCGATCCTGTCGTTAGGTG-
3’, 5’-AGGAGGCTTGGTGATGAAAA-3’ for
SLC15A4
Design and construction of siRNA sequences
against human SLC15A4- The sequences of the
siRNA specifically targeting SLC15A4 gene
were purchased from Ambion (Silencer Pre-
designed siRNA) siRNA ID # S42440 and
siRNA ID #S42441 or designed through siRNA
Wizard v3.0 (InvivoGen, USA). The sequences
were the following :
5’ CGGCTGCTATTTGAACTAT 3’ for #B,
5’GCAGACAACATATGTTTTA 3’ for #A,
5’GAGTCTTTCAGCAATCTTCTA 3’ for #C,
5’ GATTCATGTAAGATGTCTCAT 3’ for #D
5’GTGGAGAGCGCCAGAGTAA 3’ for #E, 5’
GATTCATGTAAGATGTCTCAT 3’ for #F,
and 5’ CGGCTGCTATTTGAACTAT 3’ for
scrambled. Two different vectors were used to
generate shRNA against SLC15A4; pLKO.1
vector (Addgene, Cambridge, MA) for lentiviral
knock-down system, and psiRNA-h7SK-GFPzeo
transient knock-down of SLC15A4 expression.
For both vectors, positive clones were identified
by restriction digestion and confirmed by
sequencing.
Lentiviral vector cloning- The sense and anti-
sense oligonucleotides were resuspended in
water at 20 µM, and annealed by incubating at
95°C for 4 min, 70°C for 10 min, then decreasing
the temperature to room temperature slowly
(0.1°C/min). The resulting lentiviral shRNA
vector was confirmed by restriction enzyme
digestion with Agel/EcoRI. The constructed
vector was also confirmed by DNA sequencing
with  pLKO.1 sequencing primer (5’
CAAGGCTGTTAGAGAGATAATTGGA 3’).
Lent iv irus  packaging - Packaging, and
purification of the lentivirus were performed
according to classical procedures. Briefly,
HEK293T cells were seeded 1.5 x 106 in a 10 cm
culture dish, in DMEM supplemented with 10%
FBS without antibiotics. The following day, cells
were co-transfected with the lentiviral vector (1
µg), and the lentiviral packaging/envelope
vectors psPAX2 (750 ng), pMD2.G (250 ng).
Viruses were collected from the culture
supernatant 48h post-transfection, spun at 1250
rpm for 5 min, and the media passed through a
0.45 µm filter.
Lentiviral transduction in HEK293T cells- Cells
were seeded in either 6-well plates or 24-well
plates, and then incubated with lentivirus for 3
days. Polybrene (10 µg/ml) was added to
increase the efficiency of lentiviral transduction.
Following transduction, cells were cotransfected
with NF-κB luciferase contructs and luciferase
assays were performed as above.
Western blotting- HEK293T cells were
centrifuged and the pellet was lysed with RIPA
buffer (0.5M Tris-HCl pH 7.5, 150 mM NaCl,
1% NP-40, 0.5% deoxycholic acid, protease
5inhibitor cocktail (Sigma P8340)). Total cell
lysates were boiled for 10 minutes, and
subsequently subjected to SDS-PAGE. Western
blot was performed according to a standard
protocol, using a rabbit polyclonal anti-
SLC15A4 (Santa cruz, dilution 1:500), followed
by incubation with a secondary anti-rabbit
horseradish peroxidise antibody (Thermo
Scientific  1:10,000) and an enhanced
Chemiluminescence Kit (PerkinElmer,
Massachusetts, USA ). Mouse monoclonal anti-
tubulin (Sigma, T9026, 1:10,000) was used as
loading control.
SLC15A4 expression in IBD patients— The
analysis of SLC15A4 expression in 49 CD
patients, 53 UC patients, and 23 control subjects
was performed in the context of a larger study,
which was reported elsewhere (36).
RESULTS
HEK293T cells transfected overnight
with an expression vector encoding for luciferase
under the control of an NF-κB-responsive
promoter (Igκ -luci) were stimulated with
increasing concentrations of the Nod1 ligands
iE-DAP, Tri-DAP or M-Tri-DAP for 6 hours. iE-
DAP represents the minimal peptide activating
Nod1, while Tri-DAP is the minimal naturally
occurring Nod1 ligand, and M-Tri-DAP is the
minimal muramyl peptide stimulating Nod1
(11,14) (Fig. 1A). While Tri-DAP and M-Tri-
DAP activated cells comparably, iE-DAP
appeared to be a very poor agonist, even at the
highest dose tested (10 µg/ml) (Fig. 1B). We
next stimulated cells for one to six hours with 10
µg/ml of Tri-DAP or M-Tri-DAP, and observed
that these Nod1 ligands required at least 3-4
hours of stimulation to induce measurable
activation of the NF-κB reporter gene (Fig. 1C).
We and others have previously demonstrated that
iE-DAP was able to trigger Nod1-dependent NF-
κB activation in a setting where the ligands were
added overnight together with a liposomal
transfection reagent (11,14). Therefore, the
results above likely reflect the fact that iE-DAP,
contrary to Tri-DAP or M-Tri-DAP, is
inefficiently internalized by HEK293T cells. In
order to study this question further, we used a
derivative iE-DAP that contains a lauroyl (C12)
group attached to the glutamic residue of iE-
DAP (see Fig. 1A). The rationale for such a
modification is that the fatty acids may form
micelle-like structures and display enhanced
internalization. We observed that the addition of
the fatty acid moiety to iE-DAP enhanced >100
fold the capacity of the Nod1 ligand to trigger
NF-κB (Fig. 1D). This suggests that iE-DAP
activated cells poorly as a result of defective
trafficking, rather than because of an intrinsic
inefficiency to stimulate Nod1. Next, we
questioned if the Nod1 ligands actually needed to
get access to the host cytosol to trigger cellular
responses, or if trafficking and targeting to a
specific subcellular compartment were the only
requirement for Nod1-dependent activation. To
answer this question, we pulsed HEK293T cells
with iE-DAP, Tri-DAP or M-Tri-DAP for 10
minutes in the presence of digitonin, a
membrane-permeabilizing toxin, then replaced
back the cell culture medium to neutralize the
action of digitonin, and lysed cells six hours
post-stimulation. Interestingly, in this
experimental setting, all Nod1 ligands potently
stimulated cells (Fig. 1E), therefore showing that
presentation to the host cytosol is the limiting
factor for their activating capacities. It must be
noted, however, that in this context, iE-DAP
remained a weaker agonist than Tri-DAP or M-
Tri-DAP (Fig. 1E), which correlates well with
our previous observations using a different
experimental setting (11), and may reflect a
difference in the intrinsic capacity of this
dipeptide to trigger Nod1, as compared with the
naturally occurring tripeptide forms. Together,
these results show that epithelial cells have the
capacity to internalize Nod1 ligands, that these
molecules display different trafficking abilities,
and demonstrate that these agonists must reach
the host cytosol to trigger Nod1-dependent
responses.
We next investigated the cellular
pathways responsible for the internalization of
Nod1 ligands into HEK293T cells. Nocodazole
and cytochalasin D, two drugs that block
macropinocytosis by disrupting microtubules and
actin cytoskeleton, respectively, did not affect
the capacity of Tri-DAP or M-Tri-DAP to
stimulate cells (Fig. 2A). In contrast, dynasore, a
highly specific inhibitor of dynamin (27),
potently blocked Tri-DAP- and M-Tri-DAP-
dependent activation of NF-κB (Fig. 2A). We
next took advantage of the fact that dynosore
blocks dynamin in seconds/minutes (27), to
study further the kinetics of dynamin-dependent
entry of Nod1 ligands into cells, by adding the
drug at various times before or after the addition
6of Nod1 ligand. Using this technique, we
observed that the endocytosis of Nod1 ligands is
a slow and continuous process that occurs in a
linear fashion over time (Fig. 2B). Because
dynamin is known to be crucial for both clathrin-
coated and caveolae vesicular endocytic
pathways (28,29) , we aimed to distinguish
between these two potential entry mechanisms.
Intracellular potassium depletion specifically
blocks clathrin-dependent endocytosis (28,29).
Therefore, we dissipated K+ gradients by treating
cells with valinomycin, a K+ ionophore, and
observed that this drug potently blunted the
cellular response to Nod1 ligands (Fig. 2C).
Moreover, we used methyl-β-cyclodextrin
(MβCD), a molecule that alters the fluidity of the
plasma membrane by depleting cholesterol, and
known to perturb caveolae vesicular endocytic
pathways (29). Strikingly, we observed that
MβCD actually potentiated the cellular response
to Nod1 ligands (Fig. 2D), thus excluding a role
for caveolae in mediating the entry of Nod1
ligands into HEK293T cells. Together, these
results identify clathrin-dependent endocytosis as
the mode of entry of Nod1 ligands into
HEK293T epithelial cells.
Endosomal maturation results in
progressive acidification of the vesicular lumen,
through a series of events, involving first the
action of proteins such as the Na+/H+ exchangers,
followed by further acidification mediated by the
vacuolar ATPase (V-ATPase) complex in late
endosomes and lysosomes (30). We aimed to
identify if endosomal acidification played a role
in the ability of Nod1 ligands to get exported to
the cytosol. Cells treated with carbonyl cyanide
m-chlorophenylhydrazone (CCCP), a H+
ionophore, displayed blunted responses to Nod1
ligands (Fig. 3A), thus suggesting that cellular
proton gradients are critical for the trafficking
and/or internalization of Nod1 ligands into host
cytosol. Using bafilomycin A1, a specific
inhibitor of V-ATPases, we observed that the
acidification induced by this pump was not
required for optimal trafficking of Nod1 ligands
(Fig. 3B), therefore showing that these agonists
likely exit the endocytic pathway in early/sorting
endosomes. Of note, we noticed that bafilomycin
A1 actually increased cellular responses to Nod1
ligands, which might be explained by the fact
that early endosomes, stalled at a mildly acidified
stage, are blocked at a pH close to the one
optimal for transport of Nod1 ligands out of the
endocytic machinery.
Our last results suggested that an optimal
luminal pH might exist for the efficient transport
of Nod1 ligands to the cytosol. In order to study
this question further, we developed a procedure,
relying on the transient (60 minutes)
acidification of the extracellular milieu in an
isotonic buffer in the presence of Nod1 ligands
(Fig. 4A). Strikingly, we observed that while this
procedure did not affect clathrin-mediated
endocytosis in general (Fig. 4B), it altered
greatly the cellular response to the Nod1 ligand
iE-DAP. In particular, we identified that an
optimal pH for triggering Nod1-dependent
responses existed, and was around pH 5.5-6 (Fig.
4C), which is a level of acidification commonly
observed in early endosomes (30). The fact that,
through this experimental procedure, we could
observe considerable cellular activation by iE-
DAP reinforces the idea that this ligand is not
intrinsically a poor Nod1 ligand, but rather is
impaired in its capacity to reach endosomes
acidified to 5.5-6. Through titration (Fig. 4D)
and kinetics (Fig. 4E) experiments, we refined
our observations, and noticed that as little as 1
µg/ml of iE-DAP, and a transient extracellular
acidosis for 20 minutes or more, induced
measurable iE-DAP-dependent cellular
responses. More importantly, we demonstrated
that the procedure of transient extracellular
acidosis that we developed likely bypassed
normal endosomal maturation, but still relied on
dynamin-dependent pinching off of endosomes
from the plasma membrane, as it was fully
blocked by dynasore (Fig. 4F). Next, we used
this procedure of transient extracellular acidosis
to compare the relative capacities of distinct
Nod1 ligands to trigger cellular NF-κB
responses. We first noticed that the tripeptide
ligand Tri-DAP displayed more potent activating
capacities than iE-DAP (Fig. 4G), in agreement
with our previous experiments using different
experimental systems (see above). Surprisingly,
we observed in this experimental setting that M-
Tri-DAP was almost completely unable to
trigger cellular responses (Fig. 4G), while M-Tri-
DAP and Tri-DAP displayed similar activating
capacities in normal stimulating conditions (see
Fig. 1B). These results suggest that a processing
of M-Tri-DAP into Tri-DAP likely occurs in
normally maturing endosomes, which is
bypassed in our experimental system where
endosomal acidification is artificially provoked
by transient acidosis (see also below Fig. 9).
These observations also provide evidence that
the exit of Nod1 ligands from early endosomes is
a process that is sterically gated, thus indirectly
7suggesting the existence of a specific transport
system for Nod1 ligands within the early
endosome.
We then aimed to identify if the
internalization of the Nod2 ligand, MDP,
displayed similar characteristics than that of
Nod1 ligands in HEK293T cells. When added
extracellularly for two to six hours, we observed
that MDP triggered only minimal NF-κB -
dependent cellular responses (Fig. 5A), which is
in agreement with previous reports on Nod2-
dependent responses in epithelial cells (15).
Indeed, it has been reported by several groups
that the levels of Nod2 expression in most
epithelial cells, including HEK293T, is minimal
or absent in normal conditions (31,32).
Therefore, we co-transfected overnight minimal
amounts of a Nod2 expressing vector (0.2 ng)
together with our Igκ-luci reporter construct, and
then stimulated cells with MDP for increasing
periods the following day. Using this procedure,
we noticed an increase in the overall sensitivity
of HEK293T cells to MDP (Fig. 5B), which
prompted to select this experimental setting for
further studies. Next, we observed that MDP,
like Nod1 ligands, entered cells through
dynamin-dependent and caveosome-independent
endocytosis (Fig. 5C and 5D), and that the export
out of the endocytic machinery occurred prior to
acidification dependent on the action of the V-
ATPase, as it was not blocked by bafilomycin
A1 (Fig. 5C). Finally, using the transient
extracellular acidosis procedure described above,
we observed that MDP internalization also
required an optimal pH in HEK293T cells, but
that it exhibited a broader range of pH 5.5 to 6.5
(Fig. 5E) than that of Nod1 ligands.
Next, we aimed to identify the nature of
the putative transporter, expressed in early
endosomes, which was responsible for the
sterically gated internalization of Nod1 ligands
to the cytosol. Out of the 46 families of solute
carrier (SLC) proteins, only SLC15 proteins are
known to transport di- or tri-peptides. Moreover,
SLC15 proteins cotransport oligopeptides
together with H+ and have an optimal pH for
transport around pH 5.5 to 6 (33). Therefore, we
reasoned that the putative transporter for Nod1
ligands in HEK293T cells might be a member of
the SLC15 family. We first analyzed the
expression of SLC15 proteins in HeLa,
HEK293T and MCF-7 human epithelial cell
lines by semi-quantitative PCR. The SLC15
family is composed of four members SLC15A1
to SLC15A4 in mammals. SLC15A3 was not
detected in these samples and SLC15A1 was
expressed at low levels in HEK293T cells but
not HeLa or MCF-7 (Fig. 6A). In contrast,
transcripts for SLC15A2 and SLC15A4 were
strongly expressed in the three cell lines tested
(Fig. 6A). We first investigated the potential role
of SLC15A2 in mediating the transport of Nod1
ligands by using Lys[Z(NO2)]-Val, a highly
specific inhibitor of this transporter (Ki=0.097
µM) (34). Even at the highest non-cytotoxic
dose tested (50 µM), the inhibitor failed to
inhibit Nod1 ligand-mediated NF-κB activation
(Fig. 6B), therefore suggesting that SLC15A2
was not required in our experimental system.
Similarly, cefadroxil, an antibiotic that inhibits
both SLC15A1 and SLC15A2 (34), had no
effect on Nod1 ligand-mediated NF-κB
activation (data not shown). We then
hypothesized that SLC15A4 could be implicated
in the transport of Nod1 ligands. A polyclonal
antibody raised against human SLC15A4
revealed multiple forms both at the endogenous
level and in SLC15A4-V5 overexpressed cells,
migrating at ~60 kDa and higher (Fig. 6C),
suggesting the existence of extensive post-
transcriptional modifications of SLC15A4 in
unstimulated conditions. Similar results were
obtained using another anti-SLC15A4 polyclonal
antibody (data not shown). Next, we tested a
number of siRNA constructs designed to knock-
down endogenous SLC15A4 expression by
transient transfection, and identified duplex B as
the most effective one (Fig. 6D), which was used
for functional studies. Interestingly, lentiviral-
mediated knock-down of SLC15A4 in HEK293T
cells resulted in significant decrease of NF-κB
activation by the Nod1 ligands Tri-DAP and
C12-iE-DAP in luciferase assay (Fig. 6E), thus
demonstrating that SLC15A4 was critical for
Nod1 ligand-mediated signaling in HEK293T
cells. In the case of MDP, the results were
inconclusive because of the low level of NF-κB
activation triggered by this muramyl peptide in
our experimental system.
We next investigated the sub-cellular
l o c a l i z a t i o n  o f  S L C 1 5 A 4  b y
immunofluorescence in HEK293T cells. First,
we observed that over-expressed SLC15A4-V5
colocalized with Rab5-RFP, thus showing that
this transporter was expressed in early
endosomes (Fig. 7A). Interestingly, transient
extracellular acidosis (pH 5.5), similar to the
procedure performed above in luciferase assays,
8resulted in elongation of the cells and
relocalization of SLC15A4 to the cellular poles
(Fig. 7B), where it partially colocalized with
Rab5 (Fig. 7C). It is possible that the cellular
redistribution of SLC15A4 in early endosomes at
mildly acidic pH may contribute to the
enhancement of Nod1-dependent signaling that
was observed in luciferase assays.
Recent studies have linked IBD to either
polymorphisms in genes encoding SLC15 family
members (35)  or changes in the intestinal
expression of SLC15 proteins (36). Because of
the implication of Nod1 and Nod2 in IBD, we
aimed to identify if the expression of SLC15A4
was altered in the intestine of IBD patients. We
analyzed by real-time PCR the expression of
SLC15A4 in colonic biopsies from 53 ulcerative
colitis (UC) and 49 crohn’s disease (CD)
patients, as well as 23 control subjects, and
inflamed versus non-inflammed sections were
analyzed separately. For CD patients, inflamed
versus non-inflammed sections of the terminal
ileum were also analyzed. Interestingly,
SLC15A4 expression was significantly
upregulated in inflamed areas of the colon in CD
(p<0.05) and UC (p<0.001) patients, but not in
the terminal ileum of CD patients (Fig. 8).
DISCUSSION
The results that we have presented here establish
that, in epithelial cells, muramyl peptides get
internalized and traffic via the endocytic
machinery, and most likely rely solely on the
clathrin-dependent coated pit pathway. This
entry pathway is the one generally used for
receptor-mediated endocytosis, and this raises
the possibility that a cell surface receptor might
be involved in the optimal uptake of either
muramyl peptides or peptidoglycan-derived di-
or tripeptides. In such a scenario, the interaction
of these Nod agonists with the cell surface could
be either achieved through specific recognition
of a peptidic motif by a receptor, or occur non-
specifically via electrostatic interactions. It must
be noted that our results demonstrated that iE-
DAP and Tri-DAP trigger cellular responses in a
very different fashion, and that this likely results
from an inability of iE-DAP to travel down the
endocytic pathway to mildly acidified
endosomes. It is possible that these observations
reflect a differential capacity of these peptides to
form interactions with cell  surface
receptors/proteins, prior to the invagination of
the endocytic cup.
Our results showing that Nod ligands are
internalized into host cells via endocytosis are
consistent with a number of indirect observations
of the biological activity of these molecules. In
particular, we and others have repeatedly shown
that the efficiency of Nod ligands is greatly
boosted by “co-transfecting” those ligands
overnight together with plasmidic DNA into
cat ionic  l iposomes (12 ,13) . Because
liposome/DNA complexes are known to traffic
mostly via receptor-mediated endocytosis, these
initial observations suggested that: (i) the entry
of Nod ligands into host cells can be potentiated
if these molecules traffic through this pathway,
and (ii) endocytosis is likely the most critical
limiting factor for the stimulating capacities of
Nod-activating molecules. In agreement with
this, early studies aiming at increasing the
stimulating capacities of peptidoglycan-derived
peptides or muramyl peptides demonstrated that
the covalent addition of lipophilic groups to
these structures could greatly enhance cellular
responses. For instance, the tumoricidal activity
of a lipophilic derivative of MDP on endothelial
cells has been found to be enhanced 100 to 1000
fold as compared to MDP (37). Moreover,
studies with 6-O-acyl derivatives of MDP
revealed that 6-O-(2-tetradecylhexadecanoyl)-
MDP and 6-O-(3-hydroxy-2-tetradecyl-
octadecanoyl)-MDP exhibited stronger
macrophage-stimulating effects than MDP (38).
Together, a number of convergent studies
demonstrated that delivering muramyl peptides
via liposomal or fatty acid-containing
formulat ions  great ly  improved the
immunogenicity and adjuvanticity of these
bacterial molecules (20 -23 ) . Therefore,
understanding how Nod ligands enter into cells
will help design novel rational strategies aiming
at increasing their biological activity. Moreover,
it must be noted that in natural conditions,
muramyl peptides are rarely found free in the
extracellular milieu, and are commonly
associated with other bacterial cell wall
components that carry fatty acid groups. These
include lipoproteins, lipoteichoic acid, mycolic
acids or LPS, and might play a crucial role in the
potentiation of endocytosis-mediated entry of
Nod ligands.
A recent report has demonstrated that
MDP was internalized by macrophages through
clathrin-dependent endocytosis (39) , which
supports our findings in HEK293T cells.
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to require V-ATPase-dependent endosomal
acidification, contrasting with our observations
in HEK293T cells. This might be due to
differences in the endocytic trafficking
machineries of phagocytic versus non-phagocytic
cells. Alternatively, it is possible that
macrophages and epithelial cells rely on different
transporters for Nod ligands, which would be
expressed in distinct sub-cellular compartments,
such as early endosomes or lysosomes. Indeed, a
number of muramyl peptide transporters could
exist and be differentially expressed in specific
cell types and/or sub-cellular compartments. This
hypothesis is supported by the fact that
SLC15A1 was identified as an MDP transporter
in Caco-2/bbe epithelial cells (40), but found to
be dispensable for mediating MDP entry in
macrophages (39). Similarly, SLC15A2 has
been shown to trigger transport of the Nod1
ligand iE-DAP in human upper airway epithelial
cells (41), but was found to be dispensable in our
assays. Finally, it must be noted that the knock-
down of SLC15A4 expression in HEK293T cells
did not result in a complete ablation of NF-κB
activation induced by Nod1 ligands. This
suggests that other transporters might contribute
to the transport of these peptidoglycan-derived
peptides in HEK293T cells and possibly other
cell populations.
An interesting question that emerges
from our studies is to determine if the limiting
factor for Nod-dependent activation is solely the
cytosolic presentation of its ligands, or if
endocytosis in itself participates in driving NF-
κB-dependent activation of Nod1 and Nod2.
Indeed, an argument in favor of the latter
hypothesis comes from the fact that membrane
targetting of Nod2 is required for its ability to
trigger NF-κB (42). Moreover, studies on TLR4
argue that the subcellular localization of this
protein to early endosomes is required to drive
type I interferon responses, through the specific
engagement of the adaptor protein TRAM (7).
However, our results demonstrate that the sole
presentation of Nod ligands to the host cytosol
(using the membrane permeabilizing toxin
digitonin) is sufficient to recapitulate Nod-
dependent activation of NF-κB. This strongly
suggests that endocytosis of Nod ligands is the
most efficient means for allowing access of these
molecules to the cytosol, but appears
dispensable, provided that these molecules could
access the cytosol through other means. This
observation is of importance since it implies that
Nod proteins could detect free muramyl peptides
generated by pathogenic bacteria that would have
gained access to the host cytosol, such as
Shigella or Listeria, long after these bacteria
would have ruptured the phagosome.
Our results demonstrated that an optimal
luminal pH was required for efficient delivery of
muramyl peptides into the cytosol, and this
correlates with the identification of SLC15A4 as
a transporter for Nod1 ligands in early
endosomes. Indeed, SLC15 proteins have been
shown to display optimal transport properties at
mildly acidic pH (ranging from 5.5 to 6) (33).
We have also observed that the transport of Nod1
ligands from early endosomes was sterically
gated, as iE-DAP and Tri-DAP, but not M-Tri-
DAP, were efficiently internalized in our
experimental setting of transient acidosis. Again,
these results are in agreement with the current
knowledge on the steric constraints for SLC15-
mediated transport of oligopeptides; indeed,
studies on SLC15A1 (43) and SLC15A2 (44)
have demonstrated that these transporters have a
much greater affinity for di- or tripeptides than
other oligopeptides. In this regard, cleavage of
the muramyl group by endosomal hydrolytic
enzymes such as PGRP-L/PGLYRP2 might
represent a prerequisite to SLC15A4-mediated
transport of Nod1 ligands to the cytosol.
Consequently, we hypothesize that naturally-
occurring muramyl peptides (such as M-Tri-
DAP) are likely processed by endosomal
hydrolytic enzymes, which are progressively
acquired during normal endosomal maturation
(Fig. 9). Therefore, the lack of some critical
enzymes from our artificially acidified
endosomes likely accounts for the incapacity to
process M-Tri-DAP adequately.
Together, our observations characterized
the mechanism by which Nod ligands access the
host cytosol in human epithelial cells, and
demonstrated a crucial role for endosomal uptake
and pH-dependent transport of these molecules
to the cytosol by SLC15A4. Our results provide
new avenues for the development of therapeutic
strategies aiming at either improving the uptake
of muramyl peptides, or targeting the pathway
responsible for the cytosolic transport of these
bacterial molecules. A better understanding of
how Nod proteins detect intracellular bacterial
peptidoglycan will provide insights into the
etiology of inflammatory diseases such as
asthma and Crohn’s disease, which are
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associated with mutations in NOD1 and NOD2.
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FIGURE LEGENDS
Figure 1. Differential entry of Nod1 ligands into HEK293T cells. A, Nod1- and Nod2-activating
molecules used in this study. The four Nod1-activating molecules contain the minimal motif D-Glu-
mesoDAP (iE-DAP) that triggers Nod1. C12-iE-DAP contains a fatty acid moiety (lauroyl group)
linked to the D-Glu. Muramyl dipeptide (MDP) stimulates Nod2 activity. All these molecules are
synthetic and therefore do not contain any microbial contaminant. B, HEK293T cells were transfected
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overnight with the NF-κB reporter plasmid Igκ-luci. The following day, increasing concentrations of
Nod1 ligands iE-DAP, Tri-DAP or M-Tri-DAP were added to the cell culture medium for 6h before
cell lysis. C, HEK293T cells were transfected with Igκ-luci overnight and Tri-DAP or M-Tri-DAP
were added to the cell culture medium for 1h to 6h on the following day, as indicated. D, same as (B),
but comparing the responses to increasing concentrations of iE-DAP and C12-iE-DAP. E, HEK293T
cells were transfected overnight with Igκ-luci in DMEM cell culture medium. The following day, cell
culture medium was replaced to an isotonic digitonin buffer (DB) and iE-DAP, Tri-DAP or M-Tri-
DAP (all at either 1 µg/ml or 5 µg/ml) were added to the cells in the presence of digitonin for 10
minutes. Then, cell culture medium was replaced to DMEM for 6h, before cell lysis. NS, non
stimulated. DB, Digitonin buffer.
Figure 2. Nod1 ligands enter HEK293T cells by endocytosis. In all experiments below, HEK293T
cells were first transfected overnight with Igκ-luci. A, Cells were stimulated for 6h with 5 µg/ml Tri-
DAP or M-Tri-DAP in the absence or presence of the cellular trafficking inhibitors nocodazole (Noc;
1µg/ml), cytochalasin D (CyD; 1 µg/ml) and dynasore (Dyn; 80 µM). B, Cells were stimulated for 6h
with 5 µg/ml Tri-DAP, in the presence or absence of dynasore (80 µM) added either prior to the Nod1
ligand (-30’), or at various times after the addition of Tri-DAP, as indicated. C, Cells were stimulated
for 6h with 5 µg/ml Tri-DAP in the absence or presence of valinomycin (Valino; 1 µM or 10 µM). D,
Cells were stimulated for 6h with 1 µg/ml Tri-DAP in the absence or presence of methyl-β-
cyclodextrin (MβCD; 2.5 mM or 10 mM). NS, non stimulated.
Figure 3. The internalization of Nod1 ligands is dependent on endosomal pH. In the experiments
below, HEK293T cells were first transfected overnight with Igκ-luci. A, Cells were stimulated for 6h
with 5 µg/ml Tri-DAP in the absence or presence of carbonyl cyanide m-cholorophenylhydrazone
(CCCP; 1 µM to 10 µM). B, Cells were stimulated for 6h with 5 µg/ml Tri-DAP or M-Tri-DAP in the
absence or presence of bafilomycin A1 (Baf; 10 nM to 50 nM). NS, non stimulated.
Figure 4. Extracellular acidification strongly potentiates endocytosis-mediated entry of iE-DAP. A,
Schematic representation of the experimental procedure followed to study the influence of
extracellular pH on NF-κB activation by Nod1 ligand iE-DAP. The acidification was maintained for
only 1h, in a specific isotonic buffer (IB), a period when the ligand was added. Cell medium was
replaced to DMEM pH 7 for the last 5h, before cell lysis. B, Uptake of transferrin-Alexa Fluor 568 (10
µg/ml) by HEK293T cells for 1h in IB buffer pH 7 (left) or pH 5.5 (right) was followed by
fluorescence microscopy. Overlay with differential interference contrast (DIC) is also shown. For the
experiments below (C to G), HEK293T cells were first transfected overnight with Igκ-luci, and
transient acidosis in IB was performed, as described in (A). C, Cells were stimulated for 1h with iE-
DAP (10 µg/ml) in IB buffer at different pH, as indicated. D, Cells were stimulated for 1h with various
concentrations of iE-DAP (0.1 to 10 µg/ml) in IB buffer pH 5.5. E, Cells were stimulated for various
times (0 to 60 minutes) with iE-DAP (10 µg/ml) in IB buffer pH 5.5. F, Cells were stimulated for 1h
with iE-DAP (5 µg/ml) in IB buffer pH 5.5 in the presence or absence of dynasore (Dyn; 80 µM). G,
Cells were stimulated for 1h with iE-DAP (5 µg/ml), Tri-DAP (1 µg/ml) or M-Tri-DAP (1 µg/ml) in
IB buffer pH 5.5. NS, non stimulated.
Figure 5. The Nod2 ligand MDP enters HEK293T cells by endocytosis. In all experiments below,
HEK293T cells were first transfected overnight with Igκ-luci. A, Cells were stimulated for various
times (2 to 6 hours) with muramyl dipeptide (MDP; 10 µg/ml). For the next experiments (B to E), cells
were co-transfected with an expression vector encoding for hNod2 (0.2 ng/well). B, Cells were
stimulated for various times (2 to 6 hours) with MDP (10 µg/ml). C-D, Cells were stimulated for 6
hours with MDP (10 µg/ml) in the presence or absence of (C) bafilomycin A1 (Baf ; 50 nM), dynasore
(Dyn ; 80 µM) or (D) MβCD (2.5 mM or 10 mM). E, Cells were stimulated for 1h with MDP
(10µg/ml) in IB buffer at different pH, similarly to Figure 4C. NS1, non stimulated. NS2, non
stimulated but overexpressing hNod2 (0.2 ng/well).
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Figure 6. SLC15A4 is involved in Nod1 ligand-mediated NF-κB activation in HEK293T cells. A, The
expression of SLC15 proteins was determined by RT-PCR in HeLa, HEK293T and MCF-7 human
epithelial cell lines. B, HEK293T cells were transfected overnight with Igκ-luci, and transient acidosis
in IB was performed. Cells were stimulated for 1h with M-Tri-DAP (1 µg/ml) in IB buffer pH 5.5 in
the presence or absence of increasing concentration of the SLC15A2 inhibitor Lys[Z(NO2)]-Val. C,
HEK293T cells were transfected with increasing concentration of SLC15A4-V5 expression vector,
and cell lysates analyzed by western blotting using anti-SLC15A4 antibody. * indicates a non-specific
band. D, HEK293T cells were transfected for 72h with various siRNA duplexes (constructs A to F)
against human SLC15A4 or a control non-targetting siRNA duplex (Ctr siRNA) and cell lysates
analyzed by western blotting using anti-SLC15A4 antibody. * indicates a non-specific band. The
membrane was stripped and blotted against tubulin for loading control. E, HEK293T cells transduced
for 72h with lentiviral particles expressing shRNAs against SLC15A4 or a non-targetting sequence
were transfected overnight with Igκ-luci and stimulated for 1h with Nod1 ligands (iE-DAP, Tri-DAP,
M-Tri-DAP) or Nod2 ligand MDP in acidosis conditions (IB pH 5.5), or with C12-iE-DAP normal
(non-acidified) conditions, and luciferase activity was measured 6h post-stimulation in cell lysates.
Statistical analysis was perfomed using a two-tailed unpaired t-test, and conditions for which p<0.05
were IB pH 5.5/Tri-DAP (p=0.002) and C12-iE-DAP (p=0.035). NS1, non stimulated. NS2, non
stimulated in IB pH 5.5.
Figure 7. SLC15A4 is expressed in early endosomes. A, HEK293T cells were transfected with
SLC15A4-V5 and Rab5-RFP and visualized by immunofluorescence using an anti-V5 antibody. B,
HEK293T cells were transfected with SLC15A4-V5, cultured for 1h in IB pH 7 or pH 5.5 before
fixation, and visualized by immunofluorescence using an anti-V5 antibody. C, HEK293T cells were
transfected with SLC15A4-V5 and Rab5-RFP were cultured for 1h in IB pH 5.5 before fixation, and
visualized by immunofluorescence using an anti-V5 antibody. Arrows indicate localization of
SLC15A4 and Rab5-RFP at cellular poles.
Figure 8. SLC15A4 expression is upregulated in inflamed colonic sections of IBD patients. SLC15A4
expression in colon and terminal ileum biopsies from Crohn’s disease (CD) and ulcerative colitis (UC)
patients was determined in inflamed versus non-inflamed sections, and reported to the levels of the
villin gene. * p<0.05; *** p<0.0001.
Figure 9. Schematic representation of the model for the entry of Nod1 ligands into epithelial cells. The
normal entry pathway for Nod1 ligands is presented on the left, while extracellular acidosis-induced
entry is displayed on the right. We speculate that acidosis-mediated entry allows bypassing the
progressive acidification normally observed in maturing endosomes, resulting in a different vesicular
content. In particular, our results suggest that the putative M-Tri-DAP hydrolase, which is normally
present in early endosomes, would be absent from experimentally-acidified endosomes.
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